Significance of Complete Metabolic Response to First-line Taxane/Trastuzumab and Pertuzumab for Advanced HER2+ Breast Cancer: a Single Centre Experience

Purpose: To determine the rate of complete metabolic response (CMR) to first-line therapy with a taxane, trastuzumab and pertuzumab for advanced HER2+ breast cancer and to correlate this with progression-free survival (PFS), overall survival (OS) and the development of brain metastases.

Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: H. McGrath, C. Foran, A. Midgen, G. Chander, B. Thwaites, Z. Kemp, S. Johnston, E. Kipps, M. Parton, N. Turner, A. Okines Source Type: research